Alexander Maurer, Helen Schiesser, Stephan Skawran, Antonio G Gennari, Manuel Dittli, Irene A Burger, Cäcilia Mader, Christoph Berger, Daniel Eberli, Martin W Huellner, Michael Messerli
{"title":"Frequency and intensity of [<sup>18</sup>F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET.","authors":"Alexander Maurer, Helen Schiesser, Stephan Skawran, Antonio G Gennari, Manuel Dittli, Irene A Burger, Cäcilia Mader, Christoph Berger, Daniel Eberli, Martin W Huellner, Michael Messerli","doi":"10.1259/bjro.20210084","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To assess the frequency and intensity of [<sup>18</sup>F]-prostate-specific membrane antigen (PSMA)-1007 axillary uptake in lymph nodes ipsilateral to COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) in patients with prostate cancer referred for oncological [<sup>18</sup>F]-PSMA positron emission tomography (PET)/CT or PET/MR imaging.</p><p><strong>Methods: </strong>126 patients undergoing [<sup>18</sup>F]-PSMA PET/CT or PET/MR imaging were retrospectively included. [<sup>18</sup>F]-PSMA activity (maximum standardized uptake value) of ipsilateral axillary lymph nodes was measured and compared with the non-vaccinated contralateral side and with a non-vaccinated negative control group. [<sup>18</sup>F]-PSMA active lymph node metastases were measured to serve as quantitative reference.</p><p><strong>Results: </strong>There was a significant difference in maximum standardized uptake value in ipsilateral and compared to contralateral axillary lymph nodes in the vaccination group (<i>n</i> = 63, <i>p</i> < 0.001) and no such difference in the non-vaccinated control group (<i>n = 63, p</i> = 0.379). Vaccinated patients showed mildly increased axillary lymph node [<sup>18</sup>F]-PSMA uptake as compared to non-vaccinated patients (<i>p</i> = 0.03). [<sup>18</sup>F]-PSMA activity of of lymph node metastases was significantly higher (<i>p</i> < 0.001) compared to axillary lymph nodes of vaccinated patients.</p><p><strong>Conclusion: </strong>Our data suggest mildly increased [<sup>18</sup>F]-PSMA uptake after COVID-19 vaccination in ipsilateral axillary lymph nodes. However, given the significantly higher [<sup>18</sup>F]-PSMA uptake of prostatic lymph node metastases compared to \"reactive\" nodes after COVID-19 vaccination, no therapeutic and diagnostic dilemma is to be expected.</p><p><strong>Advances in knowledge: </strong>No specific preparations or precautions (<i>e.g.</i> adaption of vaccination scheduling) need to be undertaken in patients undergoing [<sup>18</sup>F]-PSMA PET imaging after COVID-19 vaccination.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20210084"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364367/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJR open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1259/bjro.20210084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Objectives: To assess the frequency and intensity of [18F]-prostate-specific membrane antigen (PSMA)-1007 axillary uptake in lymph nodes ipsilateral to COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) in patients with prostate cancer referred for oncological [18F]-PSMA positron emission tomography (PET)/CT or PET/MR imaging.
Methods: 126 patients undergoing [18F]-PSMA PET/CT or PET/MR imaging were retrospectively included. [18F]-PSMA activity (maximum standardized uptake value) of ipsilateral axillary lymph nodes was measured and compared with the non-vaccinated contralateral side and with a non-vaccinated negative control group. [18F]-PSMA active lymph node metastases were measured to serve as quantitative reference.
Results: There was a significant difference in maximum standardized uptake value in ipsilateral and compared to contralateral axillary lymph nodes in the vaccination group (n = 63, p < 0.001) and no such difference in the non-vaccinated control group (n = 63, p = 0.379). Vaccinated patients showed mildly increased axillary lymph node [18F]-PSMA uptake as compared to non-vaccinated patients (p = 0.03). [18F]-PSMA activity of of lymph node metastases was significantly higher (p < 0.001) compared to axillary lymph nodes of vaccinated patients.
Conclusion: Our data suggest mildly increased [18F]-PSMA uptake after COVID-19 vaccination in ipsilateral axillary lymph nodes. However, given the significantly higher [18F]-PSMA uptake of prostatic lymph node metastases compared to "reactive" nodes after COVID-19 vaccination, no therapeutic and diagnostic dilemma is to be expected.
Advances in knowledge: No specific preparations or precautions (e.g. adaption of vaccination scheduling) need to be undertaken in patients undergoing [18F]-PSMA PET imaging after COVID-19 vaccination.